AstraZeneca Access 360/AZ & Me

Patient Support Services Guide 2018


Access 360
844-275-2360
AZ&Me
800-292-6363

AstraZeneca, through its Access 360 and AZ & Me programs, offers a range of patient support programs and drug-specific patient savings programs to help patients access affordable AstraZeneca medications. A complete list of AstraZeneca oncology medications, as well as their indications and support programs, is provided in the Table.

AstraZeneca also has a field-based team of Field Reimbursement Managers who can visit your office to provide information regarding how to access Astra­Zeneca medicines. To request a visit from a Field Reimbursement Manager in your area, call Access 360 at 844-275-2360.

AstraZeneca Access 360

AstraZeneca’s Access 360 program is designed to streamline access to the company’s drugs. Access 360 provides patients and providers with affordability and reimbursement support in obtaining their medications.

A Provider Portal is available at MyAccess360ProviderPortal.com. AstraZeneca also offers patient savings programs for many of its drugs for eligible commercially insured patients whose insurance does not cover the full cost of their prescriptions.

AstraZeneca Access 360 specialists can help patients with commercial insurance to access drug-specific patient support programs by identifying the patient’s prescription insurance coverage, out-of-pocket costs, and pharmacy options; and by providing support with prior authorization, insurance denial and appeals, pharmacy coordination, reimbursement, referrals to patient savings and patient assistance programs, and connections to nurse assistance or educational support programs.

Patients who are enrolled in a state or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part D, Medicaid, Medigap, Veterans Affairs, Department of Defense programs, or TRICARE.

AZ&Me Prescription Savings Program

The AZ&Me Prescription Savings Program is designed to help qualified patients without prescription drug coverage and a program for patients with Medicare Part D coverage.

Patients who qualify for the programs receive their AstraZeneca medicines at no cost. Patients must meet specific income eligibility criteria.

Eligibility

Access 360

There are no eligibility criteria to receive support from Access 360; any patient or provider can call 844-275-2360 to request support.

AZ&Me Prescription Savings Program

To be eligible for this program, patients without insurance must:

  • Meet the program’s annual household income limits
  • Reside in the United States
  • Not be eligible for Medicaid.

Patients who have Medicare Part D coverage must:

  • Be enrolled in a Medicare Part D plan
  • Meet the program’s annual household income limits
  • Have spent ≥3% of their total household income on prescription drugs through a Medicare Part D plan during the year
  • Reside in the United States
  • Not be eligible for Medicare’s Low Income Subsidy or for Medicaid.

Application & Enrollment

Access 360

An Access 360 Patient Authorization Form must be completed by the patient (or his/her legally authorized representative) to use most resources available through Access 360, including patient-specific support from our Field Reimbursement Managers.

You can facilitate patient authorization by:

  • Having your patient call Access 360 to provide authorization over the phone, or you can call to request a form be mailed to your patient with a self-addressed stamped envelope
  • Having your patient complete a Patient Authorization Form online at MyAccess360PAF.com
  • Downloading and printing a PDF of the authorization form from MyAccess360.com; having your patient complete the form; and mailing it to Access 360, One MedImmune Way, Gaithersburg, MD 20878; or faxing it to 844-329-2360.

Patient authorization allows Astra­Zeneca to support patients with:

  • Researching your patient’s insurance coverage, out-of-pocket costs, pharmacy options, and prior authorization requirements through a comprehensive benefits investigation
  • Following up on submissions with insurers and pharmacies to provide status and obtain decisions
  • Assisting with appeals support if an insurance company denies coverage
  • Reviewing eligibility for appropriate affordability programs.

Only 1 form is required per patient, and it is valid for 2 years from the date of the patient’s signature, unless a shorter period is required by state law.

AZ&Me Prescription Savings Program

The application form for this program is available online. Patients and their prescribers must fill out the application online or by hand. The completed forms must be submitted by fax (800-961-8323) or by mail to the address listed on the form. Applications and prescriptions that are not faxed from the physician’s office will be invalid.

Patients who qualify for the program are enrolled for up to 1 year, with an option to re-enroll annually.

Other Services

Lighthouse

The Lighthouse program offers support for patients who are prescribed Calquence (acalabrutinib). Once enrolled in the program, patients and their caregivers will have direct access to medically trained Lighthouse Advocates who can:

  • Address any questions or concerns 24/7
  • Provide tips on medication adherence
  • Offer consistent, personalized attention.

Table AstraZeneca Oncology Drugs

Drugs
Indications
Patient support programs

Drug
Arimidex (anastrozole)
Indication
HR-positive early breast cancer; advanced breast cancer in postmenopausal women
Patient support programs

Drug
Calquence (acalabrutinib)
Indication
Mantle-cell lymphoma after ≥1 previous therapies

Drug
Casodex (bicalutamide)
Indication
Metastatic prostate cancer
Patient support program

Drug
Faslodex (fulvestrant)
Indication
HR-positive, HER2-negative advanced breast cancer in postmenopausal women who have not received endocrine therapy; HR-positive advanced breast cancer in postmenopausal women whose disease progressed after endocrine therapy

Drug
Imfinzi (durvalumab) injection
Indication
Locally advanced or metastatic urothelial carcinoma that progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy

Drug
Iressa (gefitinib)
Indication
Metastatic NSCLC

Drug
Lynparza (olaparib)
Indication
Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults with a complete or partial response to platinum-based chemotherapy; patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer after ≥3 chemotherapies

Drug
Tagrisso (osimertinib)
Indication
Metastatic NSCLC with EGFR T790M mutation

HR indicates hormone receptor; NSCLC, non–small-cell lung cancer.